• For Patients
  • Shopping cart

MONISTAT® for Healthcare Professionals

  • Explaining VVC
  • Efficacy Data
  • Peer-Led Webinars
  • Products
  • Samples & Coupons

MONISTAT® provides the broadest treatment of yeast infections**, more than Diflucan® and Terazol® View the data

View the data

MONISTAT® relieves your patients' yeast infection symptoms 4x faster while curing just as effectively as the leading prescription1*†

View the study

For patients who are pregnant, plan to become pregnant, or have diabetes, choose MONISTAT®2,7-13*§

See why

MONISTAT® treats more species of yeast with less drug resistance2,3‡

View the data

Learn why MONISTAT® is just as effective as fluconazole

Order free MONISTAT® Sample & Savings Packs

See MONISTAT® treatment options

  • Sitemap
  • Privacy Policy
  • Contact Us

This website is intended for healthcare professionals in the US or its territories.

© 2015 Insight Pharmaceuticals, LLC, Tarrytown, NY, a Prestige Brands company.

*Compared to prescription fluconazole
**of all non-compounded drug products Diflucan® is a registered trademark of Pfizer Inc. and Terazol® is a registered trademark of Johnson & Johnson
†Based on a clinical study with MONISTAT® 1 Combination Pack Ovule® treatment vs the leading prescription product.
‡Per 2015 CDC Guidelines, options for first-line therapy of non-albicans vulvovaginal candidiasis (VVC) include longer duration therapy (7-14 days) with a non-fluconazole azole regimen.
§2015 CDC Guidelines recommend the use of 7-day topical azole therapies for treatment of vulvovaginal candidiasis (VVC) in pregnant women.

REFERENCES: 1. van Heusden AM, Merkus HM, Corbeij HS, et al. Single-dose oral fluconazole versus single-dose topical miconazole for the treatment of acute vulvovaginal candidosis. Acta Obstet Gynecol Scand. 1990;69(5):417-422. 2. Centers for Disease Control and Prevention. Sexually Transmitted Diseases Treatment Guidelines, 2015. http://www.cdc.gov/std/tg2015/tg-2015-print.pdf. Published June 5, 2015. Accessed August 14, 2015. 3. Marchaim D, Lemanek L, Bheemreddy B, Kaye KS, Sobel JD. Fluconazole-resistant Candida albicans vulvovaginitis. Obstet Gynecol. 2012;120(6):1407-1414. 4. Mintz, Martens MG. Prevalence of non-albicans Candida infections in women with recurrent vulvovaginal symptomatology. Adv Infect Dis. 2013;3(4):238-242. 5. Data on file. Insight Pharmaceuticals LLC, a Prestige Brands company. Tarrytown, NY; 2015. 6. Samra-Latif OM. Vulvovaginitis. http://emedicine.medscape.com/article/2188931-overview. Published March 27, 2014. Accessed March 12, 2015. 7. Mølgaard-Nielsen D, Svanström H, Melbye M, Hviid A, Pasternak B. Association between use of oral fluconazole during pregnancy and risk of spontaneous abortion and stillbirth. JAMA. 2016;315(1):58-67. 8. Lowes R. Low-dose fluconazole in pregnancy worries FDA. Available at: http://www.medscape.com/viewarticle/862447. Published April 26, 2016. Accessed August 26, 2017. 9. Goswami D, Goswami R, Banerjee U, et al. Pattern of Candida species isolated from patients with diabetes mellitus and vulvovaginal candidiasis and their response to single dose oral fluconazole therapy. J Infect. 2006;52(2):111-117. 10. Nyirjesy P and Sobel JD. Genital mycotic infections in patients with diabetes. Postgrad Med. 2015;125(3):33-46. 11. May M and Schindler C. Clinically and pharmacologically relevant interactions of antidiabetic drugs. Ther Adv Endocrinol Metab. 2016;7(2):69-83. 12. Diflucan [prescribing information]. New York, NY: Roerig. 2013. 13. Sola D, Rossi L, Schianca GPC, et al. Sulfonylureas and their use in clinical practice. Arch Med Sci. 2015;11(4):840-848. 14. A 2017 survey of OB/GYNs (n=200) asked: Which of the following best describes your approach to prescribing fluconazole for yeast infection in pregnant patients? (Throughout pregnancy; Trimesters 2 and 3; Trimester 3; Do not prescribe during pregnancy). 15. A 2017 survey of OB/GYNs (n=200) asked: When treating a vaginal yeast infection in women with diabetes, which do you recommend most often? (Butoconazole; Fluconazole; Miconazole; Terconazole).